Reshma Kewalramani Vertex Pharmaceuticals Inc (VRTX) insider trading activity

Reshma Kewalramani is CEO & President of VERTEX PHARMACEUTICALS INC . Currently has a direct ownership of 105,915 shares of VRTX, which is worth approximately $53 Million. The most recent transaction as insider was on Feb 17, 2023, when has been sold 9,359 shares (Common Stock) at a price of $292.85 per share, resulting in proceeds of $2,740,783. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 106K

39.78% 3M change

22.41% 12M change

Total Value Held $53 Million

Reshma Kewalramani Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 17 2023	SELL Payment of exercise price or tax liability	$2,740,783 $292.85 p/Share	9,359 Reduced 6.29%	139,355 Common Stock
Feb 13 2023	SELL Payment of exercise price or tax liability	$1,786,577 $298.26 p/Share	5,990 Reduced 3.87%	148,714 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$992,480 $294.33 p/Share	3,372 Reduced 2.13%	154,704 Common Stock
Feb 01 2023	BUY Grant, award, or other acquisition	-	68,478 Added 30.23%	158,076 Common Stock
Jan 25 2023	SELL Open market or private sale	$3,150,500 $315.05 p/Share	10,000 Reduced 10.04%	89,598 Common Stock
Aug 15 2022	SELL Open market or private sale	$3,565,846 $305.06 p/Share	11,689 Reduced 10.5%	99,598 Common Stock
Jun 24 2022	SELL Open market or private sale	$3,405,006 $291.3 p/Share	11,689 Reduced 9.52%	111,153 Common Stock
Feb 24 2022	SELL Payment of exercise price or tax liability	$1,651,074 $227.86 p/Share	7,246 Reduced 5.57%	122,842 Common Stock
Feb 17 2022	SELL Payment of exercise price or tax liability	$1,995,866 $232.51 p/Share	8,584 Reduced 6.19%	130,088 Common Stock
Feb 10 2022	SELL Payment of exercise price or tax liability	$720,590 $237.74 p/Share	3,031 Reduced 2.14%	138,672 Common Stock
Feb 01 2022	BUY Grant, award, or other acquisition	-	67,949 Added 32.41%	141,703 Common Stock
Aug 19 2021	BUY Open market or private purchase	$1,957,400 $195.74 p/Share	10,000 Added 11.94%	73,754 Common Stock
Feb 24 2021	SELL Payment of exercise price or tax liability	$630,518 $217.57 p/Share	2,898 Reduced 4.36%	63,643 Common Stock
Feb 17 2021	SELL Payment of exercise price or tax liability	$440,440 $211.75 p/Share	2,080 Reduced 3.03%	66,541 Common Stock
Feb 10 2021	SELL Payment of exercise price or tax liability	$634,342 $214.16 p/Share	2,962 Reduced 4.14%	68,621 Common Stock
Feb 03 2021	BUY Grant, award, or other acquisition	-	44,935 Added 38.56%	71,583 Common Stock

Also insider at

DNA

Ginkgo Bioworks Holdings, Inc. Healthcare

Director